Cargando…

Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer

PURPOSE: In non-metastatic prostate cancer (nmPCa) setting, it is important to early identify the patients at risk of biochemical recurrence (BCR) for immediate postoperative intervention. Our study aimed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) for predicting dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fei, Xiaochen, Du, Xinxing, Gong, Yiming, Liu, Jiazhou, Fan, Liancheng, Wang, Jiayi, Wang, Yanqing, Zhu, Yinjie, Pan, Jiahua, Dong, Baijun, Xue, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372593/ https://www.ncbi.nlm.nih.gov/pubmed/36915250 http://dx.doi.org/10.4143/crt.2022.1557

Ejemplares similares

Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer
por: Du, Xinxing, et al.
Publicado: (2023)

The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real‐world multicenter study
por: Fei, Xiaochen, et al.
Publicado: (2021)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

Engineering the MoS(2)/MXene Heterostructure for Precise and Noninvasive Diagnosis of Prostate Cancer with Clinical Specimens
por: Xie, Shaowei, et al.
Publicado: (2023)

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
por: Zhu, Yinjie, et al.
Publicado: (2023)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
por: Fan, Liancheng, et al.
Publicado: (2018)

The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP)
por: Liu, Jiazhou, et al.
Publicado: (2022)

Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone
por: Fan, Liancheng, et al.
Publicado: (2017)

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases
por: Zhu, Yinjie, et al.
Publicado: (2019)

Albumin and Fibrinogen Combined Prognostic Grade Predicts Prognosis of Patients with Prostate Cancer
por: Wang, Yanqing, et al.
Publicado: (2017)

Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S
por: Pan, Jiahua, et al.
Publicado: (2019)

Discovery of extracellular vesicles derived miR-181a-5p in patient's serum as an indicator for bone-metastatic prostate cancer
por: Wang, Yanqing, et al.
Publicado: (2021)

Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer
por: Dong, Baijun, et al.
Publicado: (2020)

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
por: Wang, Yanqing, et al.
Publicado: (2016)

Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy
por: Xu, Fan, et al.
Publicado: (2016)

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer
por: Dathathri, Eshwari, et al.
Publicado: (2022)

The Microbiome of Prostate Fluid Is Associated With Prostate Cancer
por: Ma, Xiaowei, et al.
Publicado: (2019)

PRKAR2B‐HIF‐1α loop promotes aerobic glycolysis and tumour growth in prostate cancer
por: Xia, Lei, et al.
Publicado: (2020)

AB140. Efficacy of radical prostatectomy combined with neoadjuvant chemotherapy in the treatment of locally advanced prostate cancer: preliminary experiences from a single center
por: Xue, Wei, et al.
Publicado: (2016)

Identification of cancer-associated fibroblasts subtypes in prostate cancer
por: Pan, Jiahua, et al.
Publicado: (2023)

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
por: Watahiki, Akira, et al.
Publicado: (2013)

Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia
por: Jin, Wei, et al.
Publicado: (2020)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2016)

m(6)A-induced repression of SIAH1 facilitates alternative splicing of androgen receptor variant 7 by regulating CPSF1
por: Xia, Lei, et al.
Publicado: (2022)

Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential
por: Bjerre, Marianne Trier, et al.
Publicado: (2020)

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Theil, Gerit, et al.
Publicado: (2021)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL
por: Chen, Na, et al.
Publicado: (2017)

Circulating plasma exosomal miRNA profiles serve as potential metastasis-related biomarkers for hepatocellular carcinoma
por: Huang, Chunyu, et al.
Publicado: (2021)

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer
por: Sha, Jianjun, et al.
Publicado: (2016)

Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma
por: Zhang, Yanqing, et al.
Publicado: (2017)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

Circulating non-coding RNAs in recurrent and metastatic ovarian cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2019)

Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis
por: Cheng, Hanyin, et al.
Publicado: (2011)

Small EVs-Associated DNA as Complementary Biomarker to Circulating Tumor DNA in Plasma of Metastatic Colorectal Cancer Patients
por: Galbiati, Silvia, et al.
Publicado: (2021)

Identification of characteristic metabolic panels for different stages of prostate cancer by (1)H NMR-based metabolomics analysis
por: Zhang, Xi, et al.
Publicado: (2022)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer
por: Jiang, Qi, et al.
Publicado: (2019)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_febl2hne7pkfkcfg32dfg43lqn